Royal Bank of Canada
OMED

Royal Bank of Canada’s OncoMed Pharmaceuticals, Inc. OMED Stock Holding History

Royal Bank of Canada’s Portfolio OMED Stock Details OMED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-72
Closed – – 7288
2017
Q4 		$0 Buy
72
+58
+414% +$252 ﹤0.01% 7399
2017
Q3 		$0 Buy
+14
New +$57 ﹤0.01% 7382
2017
Q2 		– Sell
-662
Closed -$6K – 7140
2017
Q1 		$6K Buy
662
+174
+36% +$1.53K ﹤0.01% 6193
2016
Q4 		$4K Buy
488
+464
+1,933% +$4.26K ﹤0.01% 6392
2016
Q3 		$0 Sell
24
-1,176
-98% -$13.7K ﹤0.01% 6869
2016
Q2 		$15K Buy
1,200
+1,126
+1,522% +$13.7K ﹤0.01% 5622
2016
Q1 		$1K Sell
74
-67
-48% -$787 ﹤0.01% 6296
2015
Q4 		$3K Sell
141
-774
-85% -$15.9K ﹤0.01% 6331
2015
Q3 		$16K Sell
915
-429
-32% -$8.6K ﹤0.01% 5676
2015
Q2 		$30K Buy
1,344
+1,165
+651% +$28.7K ﹤0.01% 5496
2015
Q1 		$5K Buy
179
+167
+1,392% +$4.24K ﹤0.01% 5773
2014
Q4 		$0 Buy
+12
New +$246 ﹤0.01% 6624
2013
Q4 		– Sell
-5,175
Closed -$80K – 6588
2013
Q3 		$80K Buy
+5,175
New +$95.9K ﹤0.01% 4594

Other funds holding OMED

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Royal Bank of Canada's OMED Position: Q1 2018 in Review

Royal Bank of Canada sold out of OncoMed Pharmaceuticals, Inc. (OMED) in Q1 2018, closing a stake of 72 shares.

Royal Bank of Canada first reported a position in OMED in Q3 2013 and held it in 13 quarters. The position peaked at $80K in Q3 2013. 66 funds tracked by Wall St. Rank hold OMED as of Q1 2018.

  • Royal Bank of Canada reported no remaining OncoMed Pharmaceuticals, Inc. position as of Q1 2018 after selling out during the quarter.
  • Royal Bank of Canada sold 72 OncoMed Pharmaceuticals, Inc. shares in Q1 2018.
  • Royal Bank of Canada first reported a position in OncoMed Pharmaceuticals, Inc. in Q3 2013 and held it in 13 quarters.
  • Royal Bank of Canada's OncoMed Pharmaceuticals, Inc. position peaked at $80K in Q3 2013.
  • 66 funds tracked by Wall St. Rank held OncoMed Pharmaceuticals, Inc. as of Q1 2018.

Based on Royal Bank of Canada's 13F filing for Q1 2018, filed 15 May 2018.